Aptose Biosciences Inc  

(Public, NASDAQ:APTO)   Watch this stock  
Find more results for OTC:LRUSF
5.95
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 4.01 - 8.80
Open     -
Vol / Avg. 0.00/21,591.00
Mkt cap 72.60M
P/E     -
Div/yield     -
EPS -1.33
Shares 11.87M
Beta 1.08
Inst. own 35%
May 5, 2015
Q1 2015 Aptose Biosciences Inc Earnings Call
May 5, 2015
Q1 2015 Aptose Biosciences Inc Earnings Release
Mar 24, 2015
Aptose Biosciences Inc at Biotechnology Industry Organization (BIO) Asia International Conference
Mar 10, 2015
Aptose Biosciences Inc at ROTH Conference
Mar 3, 2015
Aptose Biosciences to host Quarter and Seven Month Transition Period ended December 31, 2014, Conference Call and Webcast - Webcast
Feb 24, 2015
Presentation at RBC Capital Markets 2015 Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -42.00% -
Return on average equity -44.86% -
Employees 19 -
CDP Score - -

Address

2 Meridian Rd
ETOBICOKE, ON M9W 4Z7
Canada
+1-416-7981200 (Phone)
+1-416-7982200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aptose Biosciences Inc is a clinical-stage biotechnology company. The Company is engaged in discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company’s drugs include APTO-253, IL-17E and APTO-500. APTO-253 is a small molecule with potent anti-tumor activity in cancer cells via tumor suppressor induction leading to cell cycle inhibition and programmed cell death. The Company discovered IL-17E, which has potent anticancer properties against a range of solid tumors in vivo, including human melanoma, pancreatic, colon, lung, ovarian and breast tumor models. APTO-500 program focuses on discovering and developing potent small molecule inhibitors of maternal embryonic leucine zipper kinase (MELK).

Officers and directors

William Glenn Rice Chairman of the Board, President, Chief Executive Officer
Bio & Compensation  - Reuters
Gregory Kwok Lee Chow Chief Financial Officer, Senior Vice President
Bio & Compensation  - Reuters
Elizabeth Williams Finance Director, IR Contact Officer
Bio & Compensation  - Reuters
Avanish Vellanki Senior Vice President, Chief Business Officer
Bio & Compensation  - Reuters
Stephen B. Howell M.D. Chief Medical Officer
Age: 70
Bio & Compensation  - Reuters
Erich M. Platzer M.D., Ph.D. Director
Bio & Compensation  - Reuters
Denis R. Burger Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Bradley Thompson Independent Director
Bio & Compensation  - Reuters
Mark D. Vincent M.D. Independent Director
Bio & Compensation  - Reuters
Warren Whitehead Independent Director
Bio & Compensation  - Reuters